Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHRS NASDAQ:IMRX NASDAQ:MLTX NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHRSGH Research$21.19-4.6%$17.03$10.66▼$24.66$1.31B1.27316,665 shs34,004 shsIMRXImmuneering$5.13-0.1%$5.35$1.29▼$10.08$330.29M0.371.33 million shs144,967 shsMLTXMoonLake Immunotherapeutics$17.92-2.6%$17.51$5.95▼$62.75$1.28B1.011.67 million shs53,209 shsWVEWAVE Life Sciences$6.76-2.1%$8.92$5.02▼$21.73$1.30B-1.324.27 million shs342,823 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHRSGH Research+1.51%+5.71%+32.44%+51.09%+122.55%IMRXImmuneering-4.46%-1.53%-4.99%+4.26%+307.94%MLTXMoonLake Immunotherapeutics-0.11%+6.92%-2.08%+16.61%-50.28%WVEWAVE Life Sciences-1.29%-4.70%-6.63%-45.58%+8.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHRSGH Research$21.19-4.6%$17.03$10.66▼$24.66$1.31B1.27316,665 shs34,004 shsIMRXImmuneering$5.13-0.1%$5.35$1.29▼$10.08$330.29M0.371.33 million shs144,967 shsMLTXMoonLake Immunotherapeutics$17.92-2.6%$17.51$5.95▼$62.75$1.28B1.011.67 million shs53,209 shsWVEWAVE Life Sciences$6.76-2.1%$8.92$5.02▼$21.73$1.30B-1.324.27 million shs342,823 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHRSGH Research+1.51%+5.71%+32.44%+51.09%+122.55%IMRXImmuneering-4.46%-1.53%-4.99%+4.26%+307.94%MLTXMoonLake Immunotherapeutics-0.11%+6.92%-2.08%+16.61%-50.28%WVEWAVE Life Sciences-1.29%-4.70%-6.63%-45.58%+8.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHRSGH Research 2.73Moderate Buy$41.0093.45% UpsideIMRXImmuneering 2.86Moderate Buy$16.50221.39% UpsideMLTXMoonLake Immunotherapeutics 2.38Hold$23.8533.11% UpsideWVEWAVE Life Sciences 2.87Moderate Buy$27.50307.11% UpsideCurrent Analyst Ratings BreakdownLatest IMRX, WVE, GHRS, and MLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026GHRSGH Research CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/15/2026GHRSGH Research Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $35.005/15/2026GHRSGH Research Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$42.00 ➝ $39.005/12/2026MLTXMoonLake Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/12/2026MLTXMoonLake Immunotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $30.005/11/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.005/4/2026WVEWAVE Life Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $24.004/30/2026WVEWAVE Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.004/29/2026WVEWAVE Life Sciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.00 ➝ $15.004/21/2026GHRSGH Research Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026WVEWAVE Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHRSGH ResearchN/AN/AN/AN/A$4.51 per shareN/AIMRXImmuneeringN/AN/AN/AN/A$3.38 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$3.54 per shareN/AWVEWAVE Life Sciences$42.73M30.42N/AN/A$2.66 per share2.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHRSGH Research-$48.26M-$0.80N/AN/AN/AN/A-16.30%-15.77%N/AIMRXImmuneering-$56.03M-$1.38N/AN/AN/AN/A-43.33%-39.75%N/AMLTXMoonLake Immunotherapeutics-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%N/AWVEWAVE Life Sciences-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%7/30/2026 (Estimated)Latest IMRX, WVE, GHRS, and MLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026IMRXImmuneering-$0.30-$0.21+$0.09-$0.21N/AN/A5/14/2026Q1 2026GHRSGH Research-$0.27-$0.31-$0.04-$0.31N/AN/A5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/A4/29/2026Q1 2026WVEWAVE Life Sciences-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 million3/6/2026Q4 2025GHRSGH Research-$0.29-$0.23+$0.06-$0.23N/AN/A3/6/2026Q4 2025IMRXImmuneering-$0.31-$0.18+$0.13-$0.18N/AN/A2/26/2026Q4 2025WVEWAVE Life Sciences-$0.28-$0.30-$0.02-$0.30$15.68 million$17.25 million2/25/2026Q4 2025MLTXMoonLake Immunotherapeutics-$0.92-$0.92N/A-$0.92N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGHRSGH ResearchN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHRSGH ResearchN/A34.1334.13IMRXImmuneeringN/A17.5017.50MLTXMoonLake Immunotherapeutics0.398.609.27WVEWAVE Life SciencesN/A11.2611.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHRSGH Research56.90%IMRXImmuneering67.65%MLTXMoonLake Immunotherapeutics93.85%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipGHRSGH Research41.60%IMRXImmuneering22.90%MLTXMoonLake Immunotherapeutics12.02%WVEWAVE Life Sciences24.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHRSGH Research1062.03 million36.23 millionOptionableIMRXImmuneering6064.70 million49.88 millionNot OptionableMLTXMoonLake Immunotherapeutics271.73 million63.11 millionOptionableWVEWAVE Life Sciences240192.40 million145.65 millionOptionableIMRX, WVE, GHRS, and MLTX HeadlinesRecent News About These CompaniesWave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare ConferenceMay 13 at 4:05 PM | globenewswire.comGrowth Investors: Industry Analysts Just Upgraded Their Wave Life Sciences Ltd. (NASDAQ:WVE) Revenue Forecasts By 91%May 8, 2026 | finance.yahoo.comWave Life Sciences: Good Platform, Mixed Clinical Trial Data, HoldMay 7, 2026 | seekingalpha.comHC Wainwright Has Bullish Forecast for WVE Q2 EarningsMay 4, 2026 | americanbankingnews.comHC Wainwright Expects Higher Earnings for WAVE Life SciencesMay 4, 2026 | marketbeat.comCanaccord Genuity Reaffirms Their Buy Rating on Wave Life Sciences (WVE)May 3, 2026 | theglobeandmail.comA Look At Wave Life Sciences (WVE) Valuation After Sharp Year To Date Share Price DeclineMay 3, 2026 | finance.yahoo.comPictet Asset Management Holding SA Purchases 790,175 Shares of WAVE Life Sciences Ltd. $WVEMay 2, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Upgraded to "Hold" at Wall Street ZenMay 2, 2026 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by AnalystsMay 2, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Given New $43.00 Price Target at Canaccord Genuity GroupApril 30, 2026 | marketbeat.comWAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...April 29, 2026 | finance.yahoo.comWAVE Life Sciences (NASDAQ:WVE) Shares Down 7.6% - Here's What HappenedApril 29, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPSApril 29, 2026 | marketbeat.comWAVE Life Sciences Q1 Earnings Call HighlightsApril 28, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading 5.5% Higher - Time to Buy?April 28, 2026 | marketbeat.comWave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue EstimatesApril 28, 2026 | zacks.comWave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 28, 2026 | globenewswire.comWAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Should You Sell?April 24, 2026 | marketbeat.comWAVE Life Sciences (WVE) Projected to Post Earnings on TuesdayApril 24, 2026 | marketbeat.comWave Life Sciences Ltd. (WVE) Sees Strong Buy Rating From AnalystsApril 23, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMRX, WVE, GHRS, and MLTX Company DescriptionsGH Research NASDAQ:GHRS$21.19 -1.02 (-4.57%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Immuneering NASDAQ:IMRX$5.13 -0.01 (-0.12%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.MoonLake Immunotherapeutics NASDAQ:MLTX$17.92 -0.48 (-2.58%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.WAVE Life Sciences NASDAQ:WVE$6.76 -0.15 (-2.10%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
